JP5967527B2 - Appetite increase and weight gain inhibitor - Google Patents

Appetite increase and weight gain inhibitor Download PDF

Info

Publication number
JP5967527B2
JP5967527B2 JP2012141283A JP2012141283A JP5967527B2 JP 5967527 B2 JP5967527 B2 JP 5967527B2 JP 2012141283 A JP2012141283 A JP 2012141283A JP 2012141283 A JP2012141283 A JP 2012141283A JP 5967527 B2 JP5967527 B2 JP 5967527B2
Authority
JP
Japan
Prior art keywords
appetite
weight gain
food
cells
gain inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012141283A
Other languages
Japanese (ja)
Other versions
JP2014005225A (en
Inventor
勝隆 大石
勝隆 大石
幸織 山本
幸織 山本
奈々子 伊藤
奈々子 伊藤
歴 宮崎
歴 宮崎
保一 中北
保一 中北
弘挙 金田
弘挙 金田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapporo Breweries Ltd
National Institute of Advanced Industrial Science and Technology AIST
Sapporo Holdings Ltd Japan
Original Assignee
Sapporo Breweries Ltd
National Institute of Advanced Industrial Science and Technology AIST
Sapporo Holdings Ltd Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapporo Breweries Ltd, National Institute of Advanced Industrial Science and Technology AIST, Sapporo Holdings Ltd Japan filed Critical Sapporo Breweries Ltd
Priority to JP2012141283A priority Critical patent/JP5967527B2/en
Publication of JP2014005225A publication Critical patent/JP2014005225A/en
Application granted granted Critical
Publication of JP5967527B2 publication Critical patent/JP5967527B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

本発明は食欲増進かつ体重増加抑制剤に関する。   The present invention relates to an appetite enhancing and weight gain inhibitor.

ラクトバチラス・ブレビス(Lactobacillus brevis)SBC8803菌株(受託番号:FERM BP−10632)は、抗アレルギー作用を有すること(特許文献1)、アルコール性肝障害抑制作用を有すること(特許文献2)、腸管保護作用を有すること(特許文献3)等が知られている。   Lactobacillus brevis (Lactobacillus brevis) SBC8803 strain (Accession number: FERM BP-10632) has an antiallergic action (Patent Document 1), an alcoholic liver disorder suppressing action (Patent Document 2), and an intestinal tract protecting action. (Patent Document 3) and the like are known.

国際公開第2008/023663号International Publication No. 2008/023663 国際公開第2009/090961号International Publication No. 2009/090961 特開2010−83881号公報JP 2010-83881 A

本発明は、ラクトバチラス・ブレビスSBC8803菌株の新規な用途を提供することを課題とする。   An object of the present invention is to provide a novel use of the Lactobacillus brevis SBC8803 strain.

本発明者らは、SBC8803菌株の菌体又はその処理物をマウスに摂食させることにより、食欲が増進し、摂食量が増加するにもかかわらず、体重の増加が抑制されることを見出した。   The present inventors have found that feeding mice with the SBC8803 strain or treated product thereof increases appetite and suppresses the increase in body weight despite an increase in food intake. .

すなわち、本発明は、ラクトバチラス・ブレビスに属するSBC8803菌株の菌体又はその処理物を有効成分として含有する食欲増進かつ体重増加抑制剤を提供する。   That is, the present invention provides an appetite-enhancing and weight gain-inhibiting agent containing the SBC8803 strain belonging to Lactobacillus brevis or a processed product thereof as an active ingredient.

上記食欲増進かつ体重増加抑制剤によれば、食欲を増進させるにもかかわらず、体重の増加を抑制するという極めて意外な効果が奏される。したがって、例えば、体重は増加させたくないが食欲を増進させたい時(例えば、夏バテ等で食欲が無い時の食欲増進、お年寄りの食欲増進)、及び成長期の子供の偏食対策時等に有効である。   According to the above-mentioned appetite increase and weight gain inhibitor, an extremely surprising effect of suppressing an increase in body weight is achieved in spite of an increase in appetite. Therefore, for example, when you do not want to increase weight but want to increase appetite (for example, increase appetite when there is no appetite, summer appetite, increase appetite for the elderly, etc.) It is.

なお、ラクトバチラス・ブレビスSBC8803菌株は、2006年6月28日に独立行政法人産業技術総合研究所特許生物寄託センター(日本国茨城県つくば市東1丁目1番地1 中央第6(郵便番号305−8566))に寄託された、受託番号がFERM BP−10632の菌株である。本明細書において、この菌株を「SBL88株」とも称する。   In addition, the Lactobacillus brevis SBC8803 strain was established on June 28, 2006 at the National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Center (1st, 1st East, 1st Street, Tsukuba City, Ibaraki Prefecture, Japan, 6th postal code 305-8586). ), And the accession number is FERM BP-10632. In the present specification, this strain is also referred to as “SBL88 strain”.

ラクトバチラス・ブレビスは、古くから発酵食品に利用されている乳酸菌の一種であり、生体への安全性が確立されている。したがって、本発明の食欲増進かつ体重増加抑制剤は、生体への安全性が高く、長期間継続的に摂取可能である。そのため、医薬品成分、飲食品成分、飲食品添加物等として使用することができる。   Lactobacillus brevis is a type of lactic acid bacterium that has been used for fermented foods for a long time, and has been established to be safe for living organisms. Therefore, the appetite promoting and weight gain suppressing agent of the present invention is highly safe to the living body and can be taken continuously for a long period of time. Therefore, it can be used as a pharmaceutical ingredient, a food / beverage product component, a food / beverage product additive, and the like.

本発明によれば、生体への安全性が高く、飲食品の成分としても使用可能な新規の食欲増進かつ体重増加抑制剤が提供される。また、上記食欲増進かつ体重増加抑制剤を含有する医薬品、飲食品、飲食品添加物等が提供される。   ADVANTAGE OF THE INVENTION According to this invention, the safety improvement with respect to a biological body and the novel appetite increase and weight gain inhibitor which can be used also as a component of food-drinks are provided. Moreover, the pharmaceutical, food / beverage products, food / beverage product additive containing the said appetite increase and weight gain inhibitor are provided.

実施例におけるマウスの摂餌量推移を示すグラフである。It is a graph which shows the food intake amount transition of the mouse | mouth in an Example. 実施例におけるマウスの体重推移を示すグラフである。It is a graph which shows the weight transition of the mouse | mouth in an Example.

以下、本発明の好適な実施形態について詳細に説明する。   Hereinafter, preferred embodiments of the present invention will be described in detail.

本発明の食欲増進かつ体重増加抑制剤は、ラクトバチラス・ブレビスに属するSBC8803菌株の菌体又はその処理物を有効成分として含有する。   The appetite promoting and weight gain inhibitor of the present invention contains, as an active ingredient, the bacterial body of SBC8803 strain belonging to Lactobacillus brevis or a processed product thereof.

本発明の食欲増進かつ体重増加抑制剤には、上記菌体及び上記菌体の処理物を1種単独で用いてもよく、2種以上を組み合わせて用いてもよい。   For the appetite promoting and body weight gain inhibitor of the present invention, the above bacterial cells and the processed product thereof may be used singly or in combination of two or more.

上記菌体は、生菌体及び死菌体のいずれであってもよい。菌体は、生菌を培養することにより大量に生産することができる。培地は、液体培地及び固体培地のいずれでもよいが、窒素源及び炭素源を含有するものが好ましい。窒素源としては、肉エキス、ペプトン、グルテン、カゼイン、酵母エキス、アミノ酸等を、また、炭素源としては、グルコース、キシロース、フルクトース、イノシトール、マルトース、水アメ、麹汁、デンプン、バカス、フスマ、糖蜜、グリセリン等を用いることができる。また、無機質として、硫酸アンモニウム、リン酸カリウム、塩化マグネシウム、食塩、鉄、マンガン、モリブデン等を添加することができ、更にビタミン等を添加することができる。好適な培地としては、MRS培地、LBS培地、Rogosa培地、WYP培地、GYP培地等が挙げられる。   The microbial cells may be live cells or dead cells. Bacteria can be produced in large quantities by culturing viable bacteria. The medium may be either a liquid medium or a solid medium, but preferably contains a nitrogen source and a carbon source. Nitrogen sources include meat extract, peptone, gluten, casein, yeast extract, amino acids, etc., and carbon sources include glucose, xylose, fructose, inositol, maltose, water candy, soup, starch, bacus, bran, Molasses, glycerin and the like can be used. Further, ammonium sulfate, potassium phosphate, magnesium chloride, sodium chloride, iron, manganese, molybdenum and the like can be added as inorganic substances, and vitamins and the like can be further added. Suitable media include MRS media, LBS media, Rogosa media, WYP media, GYP media and the like.

上記菌株の培養は、ラクトバチラス・ブレビスに属する菌株の培養に常用されている培養方法に従って行なうことができる。例えば、培養温度は通常20〜50℃、好ましくは25〜40℃、より好ましくは30℃である。培養時間は通常6〜62時間であり、好ましくは12〜48時間であり、より好ましくは15〜30時間である。培地のpHは通常3〜8、好ましくは4〜7であり、より好ましくは6〜7である。培養はインキュベーター中で行ってもよく、また、培養の際は通気振とうしてもよい。   The above strain can be cultured according to a culture method commonly used for culturing strains belonging to Lactobacillus brevis. For example, the culture temperature is usually 20-50 ° C, preferably 25-40 ° C, more preferably 30 ° C. The culture time is usually 6 to 62 hours, preferably 12 to 48 hours, and more preferably 15 to 30 hours. The pH of the medium is usually 3 to 8, preferably 4 to 7, and more preferably 6 to 7. Cultivation may be performed in an incubator, or aeration and shaking may be performed during the cultivation.

菌体の処理物としては、上記菌体(生菌体又は死菌体)に、加熱、加圧、乾燥、粉砕、破砕、破壊又は自己溶解等の処理を行って得られる処理物が挙げられる。これらの処理は2種以上を組み合わせてもよい。菌体の処理物としては、例えば、菌体を100℃以上で数分以上加熱して得られる処理物(例えば、菌体に、105〜125℃の温度で10分以上、オートクレーブ処理を施して得られる処理物)、菌体に対して凍結乾燥、噴霧乾燥等を行って得られる処理物、菌体を有機溶媒(アセトン、エタノール等)に接触させて得られる処理物、菌体を酸若しくはアルカリ溶液に接触させて得られる処理物、菌体を酵素的に破砕して得られる処理物、又は菌体を超音波、フレンチプレス等で物理的に破壊して得られる処理物が挙げられる。このような菌体処理物は、未処理菌体(特に生菌体)と比較して、取り扱いが容易な点で好適である。   Examples of treated cells include treated products obtained by subjecting the above-mentioned cells (live cells or dead cells) to treatment such as heating, pressurization, drying, crushing, crushing, breaking, or self-dissolution. . Two or more of these treatments may be combined. As the treated product of the microbial cells, for example, a treated product obtained by heating the microbial cells at 100 ° C. or more for several minutes or more (for example, by subjecting the microbial cells to autoclaving at a temperature of 105 to 125 ° C. for 10 minutes or more. Processed product), processed product obtained by freeze-drying, spray-drying, etc. on the bacterial cells, processed product obtained by contacting the bacterial cells with an organic solvent (acetone, ethanol, etc.), A treated product obtained by contacting with an alkaline solution, a treated product obtained by enzymatic disruption of bacterial cells, or a treated product obtained by physically destroying the bacterial cells with ultrasonic waves, a French press, or the like can be used. Such a cell-treated product is preferable in that it is easy to handle as compared with untreated cells (particularly live cells).

本発明の食欲増進かつ体重増加抑制剤は、固体(例えば、凍結乾燥させて得られる粉末)、液体(水溶性又は脂溶性の溶液又は懸濁液)、ペースト等のいずれの形状であってもよく、また、散剤、丸剤、顆粒剤、錠剤、シロップ剤、トローチ剤、カプセル剤等のいずれの剤形であってもよい。   The appetite enhancing and weight gain inhibitor of the present invention may be in any form such as a solid (for example, a powder obtained by freeze-drying), a liquid (a water-soluble or fat-soluble solution or suspension), a paste, or the like. In addition, any dosage form such as powder, pill, granule, tablet, syrup, troche, capsule and the like may be used.

上述の各種製剤は、有効成分である上記菌体又はその処理物のみからなるものであってもよく、例えば、当該菌体又はその処理物を上記剤形に成形することによって調製することができる。上述の各種製剤はまた、上記有効成分と、薬学的に許容される添加剤(賦形剤、結合剤、滑沢剤、崩壊剤、乳化剤、界面活性剤、基剤、溶解補助剤、懸濁化剤等)とを混和し、成形することによって調製することもできる。この場合の上記有効成分の含有量は、製剤全量を基準として、例えば、0.5〜50質量%である。   The above-mentioned various preparations may consist only of the above-mentioned fungus bodies or processed products thereof, which are active ingredients, and can be prepared, for example, by molding the fungus bodies or treated products thereof into the above dosage form. . The above-mentioned various preparations also contain the above active ingredients and pharmaceutically acceptable additives (excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, solubilizers, suspensions). It is also possible to prepare the mixture by mixing with an agent and the like. In this case, the content of the active ingredient is, for example, 0.5 to 50% by mass based on the total amount of the preparation.

例えば、賦形剤としては、ラクトース、スクロース、デンプン、デキストリン等が挙げられる。結合剤としては、ポリビニルアルコール、アラビアゴム、トラガント、ゼラチン、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロースナトリウム、ポリビニルピロリドン等が挙げられる。滑沢剤としては、ステアリン酸マグネシウム、ステアリン酸カルシウム、タルク等が挙げられる。崩壊剤としては、結晶セルロース、寒天、ゼラチン、炭酸カルシウム、炭酸水素ナトリウム、デキストリン等が挙げられる。乳化剤又は界面活性剤としては、Tween60、Tween80、Span80、モノステアリン酸グリセリン等が挙げられる。基剤としては、セトステアリルアルコール、ラノリン、ポリエチレングリコール、米糠油、魚油(DHA、EPA等)、オリーブ油等が挙げられる。溶解補助剤としては、ポリエチレングリコール、プロピレングリコール、炭酸ナトリウム、クエン酸ナトリウム、Tween80等が挙げられる。懸濁化剤としては、Tween60、Tween80、Span80、モノステアリン酸グリセリン、ポリビニルアルコール、ポリビニルピロリドン、メチルセルロース、ヒドロキシメチルセルロース、アルギン酸ナトリウム等が挙げられる。   For example, the excipient includes lactose, sucrose, starch, dextrin and the like. Examples of the binder include polyvinyl alcohol, gum arabic, tragacanth, gelatin, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone and the like. Examples of the lubricant include magnesium stearate, calcium stearate, talc and the like. Examples of the disintegrant include crystalline cellulose, agar, gelatin, calcium carbonate, sodium bicarbonate, dextrin and the like. Examples of the emulsifier or surfactant include Tween 60, Tween 80, Span 80, and glyceryl monostearate. Examples of the base include cetostearyl alcohol, lanolin, polyethylene glycol, rice bran oil, fish oil (DHA, EPA, etc.), olive oil and the like. Examples of the solubilizer include polyethylene glycol, propylene glycol, sodium carbonate, sodium citrate, Tween 80 and the like. Examples of the suspending agent include Tween 60, Tween 80, Span 80, glyceryl monostearate, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxymethyl cellulose, sodium alginate and the like.

本発明の食欲増進かつ体重増加抑制剤は、ヒトに投与しても、非ヒト哺乳動物に投与してもよい。投与量及び投与方法は、投与される個体の状態、年齢等に応じて適宜決定することができる。好適な投与方法としては、例えば、経口投与が挙げられる。投与量及び投与方法の一例として、食欲増進かつ体重増加抑制剤を有効成分量が0.5mg〜500mgとなる量を1日1回経口で投与する方法を挙げることができる。   The appetite promoting and weight gain inhibitor of the present invention may be administered to humans or non-human mammals. The dosage and administration method can be appropriately determined according to the condition, age, etc. of the individual to be administered. Suitable administration methods include, for example, oral administration. As an example of the dosage and administration method, there can be mentioned a method in which an appetite enhancing and weight gain inhibitor is orally administered in an amount of 0.5 to 500 mg of an active ingredient once a day.

本発明の食欲増進かつ体重増加抑制剤は、医薬品成分、飲食品成分、飲食品添加物、飼料成分、飼料添加物等として使用することができる。   The appetite promoting and weight gain inhibitor of the present invention can be used as a pharmaceutical ingredient, a food / beverage product ingredient, a food / beverage food additive, a feed ingredient, a feed additive, and the like.

例えば、本発明の食欲増進かつ体重増加抑制剤は、水、清涼飲料水、果汁飲料、乳飲料、アルコール飲料、パン類、麺類、米類、豆腐、乳製品、醗酵食品、発酵乳、醤油、味噌、菓子類等の飲食品への添加物として使用することができる。これらの飲食品は、当分野で通常使用される他の添加物を更に含有してもよく、そのような添加物としては、例えば、苦味料、香料、リンゴファイバー、大豆ファイバー、肉エキス、黒酢エキス、ゼラチン、コーンスターチ、蜂蜜、動植物油脂;グルコース、フルクトース等の単糖類;スクロース等の二糖類;デキストロース、デンプン等の多糖類;エリスリトール、キシリトール、ソルビトール、マンニトール等の糖アルコール類;ビタミンC等のビタミン類、が挙げられる。本発明の食欲増進かつ体重増加抑制剤はまた、特定保健用食品、特別用途食品、栄養補助食品、健康食品、機能性食品、病者用食品等の成分として使用することもできる。本発明の食欲増進かつ体重増加抑制剤を含有する飲食品は、上記菌株で牛乳、脱脂乳、豆乳、野菜、果汁、穀物、及びそれらの加工品等を発酵させて得られる発酵物であってもよい。   For example, the appetite promoting and weight gain inhibitor of the present invention is water, soft drinks, fruit juice drinks, milk drinks, alcoholic drinks, breads, noodles, rice, tofu, dairy products, fermented foods, fermented milk, soy sauce, It can be used as an additive to food and drink such as miso and confectionery. These foods and drinks may further contain other additives usually used in the art, and examples of such additives include bitters, flavors, apple fibers, soybean fibers, meat extracts, blacks. Vinegar extract, gelatin, corn starch, honey, animal and vegetable oils; monosaccharides such as glucose and fructose; disaccharides such as sucrose; polysaccharides such as dextrose and starch; sugar alcohols such as erythritol, xylitol, sorbitol, and mannitol; vitamin C and the like Vitamins. The appetite-enhancing and weight gain inhibitor of the present invention can also be used as a component for foods for specified health use, foods for special uses, dietary supplements, health foods, functional foods, foods for the sick, and the like. A food and drink containing the appetite enhancing and weight gain inhibitor of the present invention is a fermented product obtained by fermenting milk, skim milk, soy milk, vegetables, fruit juice, cereals, processed products thereof, and the like with the above strains. Also good.

以下、実施例等に基づいて本発明をより具体的に説明する。ただし、本発明は以下の実施例に限定されるものではない。   Hereinafter, the present invention will be described more specifically based on examples and the like. However, the present invention is not limited to the following examples.

〔実施例1〕
(試験方法)
<菌体処理物の調製>
SBL88株を培地(組成:マルトース2質量%、酵母エキス1.4質量%、酢酸ナトリウム0.5質量%、硫酸マンガン0.005質量%、pH6.5〜7.0)に植菌し、30℃で1日間静置培養した。得られた培養液(約8×10cfu/ml)を8,000rpmで10分間遠心分離し、菌体を回収した。回収した菌体を蒸留水に再懸濁し、8,000rpmで10分遠心分離し、菌体を回収した。この操作を2度繰り返した。回収した菌体を蒸留水に懸濁し、105℃で10分間加熱処理した後、凍結乾燥して加熱処理菌体粉末(菌体処理物)を得た。
[Example 1]
(Test method)
<Preparation of treated cells>
SBL88 strain was inoculated into a medium (composition: maltose 2 mass%, yeast extract 1.4 mass%, sodium acetate 0.5 mass%, manganese sulfate 0.005 mass%, pH 6.5-7.0), 30 The culture was allowed to stand at 1 ° C. for 1 day. The obtained culture solution (about 8 × 10 8 cfu / ml) was centrifuged at 8,000 rpm for 10 minutes, and the cells were collected. The collected cells were resuspended in distilled water and centrifuged at 8,000 rpm for 10 minutes to collect the cells. This operation was repeated twice. The collected cells were suspended in distilled water, heat-treated at 105 ° C. for 10 minutes, and then freeze-dried to obtain heat-treated cell powder (cell-treated product).

<マウス飼料の調製>
粉末飼料CE−2(日本クレア株式会社製)にSBL88株の菌体処理物を0.5質量%添加した後、ペレット化して菌体処理物を含むマウス飼料(SBL88含有CE−2飼料)を調製した。対照として、粉末飼料CE−2をペレット化して菌体処理物を含まないマウス飼料(CE−2飼料)を調製した。
<Preparation of mouse feed>
After adding 0.5% by mass of the cell-treated product of SBL88 strain to powdered feed CE-2 (manufactured by Clea Japan Co., Ltd.), pelleted mouse feed containing the cell-treated product (CE-2 feed containing SBL88) Prepared. As a control, a powdered feed CE-2 was pelleted to prepare a mouse feed (CE-2 feed) that does not contain a processed bacterial cell product.

<マウスの飼育>
C3H/HeN系統のマウス(3週齢の雄性、日本エスエルシー株式会社)を2週間馴化飼育した。馴化後、マウスを2群(各群5匹)に分け、対照群には食餌としてCE−2飼料を、被検群(SBL88群)には食餌としてSBL88含有CE−2飼料を与え、4週間自由摂食させた。
<Mouse breeding>
C3H / HeN strain mice (3 weeks old male, Japan SLC Co., Ltd.) were bred for 2 weeks. After acclimatization, the mice were divided into 2 groups (5 animals for each group), CE-2 diet was given to the control group, and SBL88-containing CE-2 diet was given to the test group (SBL88 group) for 4 weeks. Ad libitum.

<摂餌量及び体重の測定>
自由摂食期間中1週間毎に摂餌量及びマウスの体重を測定した。摂餌量(g/day)は、1週間の餌の減少量を測定し、1日あたりの減少量に換算して求めた。各群の摂餌量及び体重は、各群5匹のマウスの平均値として求めた。有意差の有無は、Studentのt検定を用いて判定した。
<Measurement of food intake and body weight>
Food intake and mouse body weight were measured every week during the free feeding period. The amount of food intake (g / day) was determined by measuring the amount of decrease in food per week and converting it to the amount of decrease per day. The food intake and body weight of each group were determined as an average value of 5 mice in each group. The presence or absence of a significant difference was determined using Student's t test.

(結果)
図1は、マウスの摂餌量推移を示すグラフである。試験開始2週間後(飼育期間2週)には、対照群と比べてSBL88群の摂餌量は危険率5%で有意に増加した。この傾向は試験開始3週間後(飼育期間3週)及び4週間後(飼育期間4週)にかけてより顕著となり、いずれも対照群と比べてSBL88群の摂餌量は危険率5%で有意に増加した。
(result)
FIG. 1 is a graph showing changes in the amount of food consumed by mice. Two weeks after the start of the test (2 weeks of breeding period), the amount of food consumed in the SBL88 group significantly increased at a risk rate of 5% compared to the control group. This tendency becomes more prominent 3 weeks after the start of the test (3 weeks of breeding) and 4 weeks after (4 weeks of breeding), both of which are significantly higher in the SBL88 group compared to the control group at a risk rate of 5%. Increased.

図2は、マウスの体重推移を示すグラフである。試験開始直後(飼育期間0週)の対照群及びSBL88群の体重は同程度(対照群:21.33±0.45g、SBL88群:21.11±0.36g)であった。SBL88群の摂餌量が対照群と比べて増加した試験開始2週間後(飼育期間2週)から4週間後(飼育期間4週)にかけては、驚くべきことに、SBL88群の体重は、対照群の体重と差がなく(統計的に有意差なし)、むしろ対照群と比べて体重増加が抑制される傾向にあった。   FIG. 2 is a graph showing the weight transition of the mouse. The weights of the control group and the SBL88 group were the same (control group: 21.33 ± 0.45 g, SBL88 group: 21.11 ± 0.36 g) immediately after the start of the test (bred period 0 weeks). Surprisingly, from 2 weeks after the start of the test when the amount of food in the SBL88 group was increased compared to the control group (2 weeks of breeding period) to 4 weeks (4 weeks of breeding period), the body weight of the SBL88 group was There was no difference in body weight of the group (no statistically significant difference), but rather there was a tendency to suppress weight gain compared to the control group.

SBL88群における食欲が増進する一方で体重増加が抑制される機構については明らかではないが、その理由として、例えば、SBL88株の菌体処理物を摂取することにより新陳代謝が活性化すること、食欲の増進によって体力が向上し活動量(消費)も活性化すること、等が考えられる。   The mechanism by which weight gain is suppressed while the appetite in the SBL88 group is promoted is not clear, but the reason for this is, for example, that the metabolism is activated by ingesting the treated product of SBL88 strain, It is conceivable that the physical strength is improved and the amount of activity (consumption) is activated by the promotion.

本発明の食欲増進かつ体重増加抑制剤によれば、食欲を増進させるにもかかわらず、体重の増加を抑制するという極めて意外な効果が奏される。したがって、例えば、体重は増加させたくないが食欲を増進させたい時(例えば、夏バテ等で食欲が無い時の食欲増進、お年寄りの食欲増進)、及び成長期の子供の偏食対策時等に摂取又は服用するための飲食品、医薬品等に利用することができる。   According to the appetite enhancing and weight gain inhibitor of the present invention, an extremely surprising effect of suppressing an increase in body weight is achieved in spite of an increase in appetite. Therefore, for example, when you don't want to increase your weight but want to increase your appetite (for example, when you have no appetite due to summer batter, etc.) Or it can utilize for the food-drinks, pharmaceuticals, etc. for taking.

Claims (4)

ラクトバチラス・ブレビス(Lactobacillus brevis)に属するSBC8803(受託番号:FERM BP−10632)菌株の菌体又はその処理物を有効成分として含有する食欲増進かつ体重増加抑制剤。   An appetite-enhancing and weight gain inhibitor containing, as an active ingredient, a cell of SBC8803 (accession number: FERM BP-10632) belonging to Lactobacillus brevis or a processed product thereof. ラクトバチラス・ブレビス(Lactobacillus brevis)に属するSBC8803(受託番号:FERM BP−10632)菌株の菌体又はその処理物を有効成分として含有する食欲増進かつ体重増加抑制用医薬品。 A pharmaceutical product for increasing appetite and suppressing weight gain, comprising, as an active ingredient, a cell of SBC8803 (accession number: FERM BP-10632) belonging to Lactobacillus brevis or a processed product thereof . ラクトバチラス・ブレビス(Lactobacillus brevis)に属するSBC8803(受託番号:FERM BP−10632)菌株の菌体又はその処理物を有効成分として含有する食欲増進かつ体重増加抑制用飲食品。 A food and drink for promoting appetite and suppressing weight gain, comprising, as an active ingredient, a cell of SBC8803 (accession number: FERM BP-10632) belonging to Lactobacillus brevis or a processed product thereof . ラクトバチラス・ブレビス(Lactobacillus brevis)に属するSBC8803(受託番号:FERM BP−10632)菌株の菌体又はその処理物を有効成分として含有する食欲増進かつ体重増加抑制用飲食品添加物。 A food additive for increasing appetite and suppressing body weight gain, comprising as an active ingredient a cell of SBC8803 (accession number: FERM BP-10632) belonging to Lactobacillus brevis or a processed product thereof.
JP2012141283A 2012-06-22 2012-06-22 Appetite increase and weight gain inhibitor Active JP5967527B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012141283A JP5967527B2 (en) 2012-06-22 2012-06-22 Appetite increase and weight gain inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012141283A JP5967527B2 (en) 2012-06-22 2012-06-22 Appetite increase and weight gain inhibitor

Publications (2)

Publication Number Publication Date
JP2014005225A JP2014005225A (en) 2014-01-16
JP5967527B2 true JP5967527B2 (en) 2016-08-10

Family

ID=50103312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012141283A Active JP5967527B2 (en) 2012-06-22 2012-06-22 Appetite increase and weight gain inhibitor

Country Status (1)

Country Link
JP (1) JP5967527B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061567A (en) * 2012-03-19 2017-03-30 サッポロホールディングス株式会社 Serotonin secretagogue

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6813974B2 (en) * 2016-07-14 2021-01-13 株式会社明治 Ghrelin secretagogue
JP6515244B2 (en) * 2018-11-14 2019-05-15 株式会社明治 Ghrelin secretagogue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4580542B2 (en) * 2000-05-17 2010-11-17 株式會社バイオニア Microorganism for treating obesity or diabetes and pharmaceutical composition containing the microorganism
JP4540376B2 (en) * 2004-03-24 2010-09-08 有限会社アーク技研 Lactic acid bacteria production substances
JP5945092B2 (en) * 2010-08-11 2016-07-05 サッポロホールディングス株式会社 Neutral fat reducing agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061567A (en) * 2012-03-19 2017-03-30 サッポロホールディングス株式会社 Serotonin secretagogue

Also Published As

Publication number Publication date
JP2014005225A (en) 2014-01-16

Similar Documents

Publication Publication Date Title
JP7193469B2 (en) Muscle building composition
JP5203393B2 (en) Alcoholic liver injury inhibitor
KR102543494B1 (en) Novel probiotics and use thereof
WO2017130859A1 (en) Neuronal cell death inhibitor
JP5945092B2 (en) Neutral fat reducing agent
JP4565057B2 (en) Novel lactic acid bacteria with high ability to induce immunoglobulin A
US11141442B2 (en) Tributyrin compositions and methods therefor
JP5943342B2 (en) Circadian rhythm improving agent
JP2020164493A (en) Composition for suppressing muscle inflammation and composition for suppressing intestinal inflammation
JP5967527B2 (en) Appetite increase and weight gain inhibitor
JP6557605B2 (en) Intestinal barrier function enhancer containing lactic acid bacteria
JP6261688B2 (en) QOL improvement or persistence agent
WO2018207741A1 (en) PGC-1α BIOSYNTHESIS PROMOTER AND SLOW-TO-FAST MUSCLE CONVERSION INHIBITOR
JP7430312B2 (en) Composition for promoting intestinal short-chain fatty acid production and food and beverages containing the same
WO2014199698A1 (en) Body temperature-elevating agent
JP5815105B2 (en) Neutral fat reducing agent
JP2018174772A (en) Methods for producing lactic acid bacteria, and compositions for immunity modulation
TW202335676A (en) Intestine immunostimulant and IgA generation promoter for ensuring Apilactobacillus lactobacillus having IgA generation promotion effect and immunostimulation function
JP6594623B2 (en) Norovirus infection prevention agent
JP2021182889A (en) Composition for improving pulmonary functions, and composition for preventing, treating or alleviating pulmonary diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160624

R150 Certificate of patent or registration of utility model

Ref document number: 5967527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250